KR920700601A - 피부투과 증진제 조성물 - Google Patents

피부투과 증진제 조성물

Info

Publication number
KR920700601A
KR920700601A KR1019910701172A KR910701172A KR920700601A KR 920700601 A KR920700601 A KR 920700601A KR 1019910701172 A KR1019910701172 A KR 1019910701172A KR 910701172 A KR910701172 A KR 910701172A KR 920700601 A KR920700601 A KR 920700601A
Authority
KR
South Korea
Prior art keywords
pharmacologically active
composition
active substance
ether
diethylene glycol
Prior art date
Application number
KR1019910701172A
Other languages
English (en)
Other versions
KR950010324B1 (ko
Inventor
치앙 치아-밍
더블유. 클레어리 게리
Original Assignee
더블유. 클레어리 게리
시그너스 리서취 코오퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23276050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920700601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더블유. 클레어리 게리, 시그너스 리서취 코오퍼레이션 filed Critical 더블유. 클레어리 게리
Publication of KR920700601A publication Critical patent/KR920700601A/ko
Application granted granted Critical
Publication of KR950010324B1 publication Critical patent/KR950010324B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Amplifiers (AREA)

Abstract

내용 없음

Description

피부투과 증진제 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예 6에서 얻어지는 조성물의 적정 비율화 상태의 결과를 나타내는 표시도이다.

Claims (11)

  1. 다음으로 구성되는 약물학적 활성물질의 경피전달에 유용한 조성물 (a) 치료학적 유효량을 갖는 최소한 하나 이상의 약물학적 활성물질; 및 (b) 상기 최소한 하나 이상의 약물학적 활성물질의 경피침투를 증진시키는 유효량의 투과정진제조성물; 이 증진제조성물은 디에틸렌글리콜모노에틸에테르, 디에틸렌글리콜모노메틸에테르, 및 이들의 혼합물로 구성되는 군에서 선택된 에테르성분과 구조식[CH3(CH2)m COO]nR (여기서 m은 8 내지 16범위의 정수, n은 1 또는 2 및 R은 하나 또는 둘의 히드록실기로 치환되거나 또는 무치환 저금알킬(C1-C3) 잔기이다.)로 주어지는 에스테르 성분으로 구성되는 조성물.
  2. 제1항에 있어서, n이 10인 조성물.
  3. 제1항 또는 제2항에 있어서, 에테르성분이 디에틸렌글리콜모노에틸에테르인 조성물.
  4. 제1항에 있어서, 에테르성분은 디에틸렌글리콜모노에틸에테르이고, 에스테르 성분은 프로필렌 글리콜 모노로레이트, 이거나 또는 프로필렌 글리콜 디로 레이트와 프로필렌 글리콜 모노로레이트 같이 쓰는 조성물.
  5. 제1항에 있어서, 최소한 하나 이상의 약물학적 활성물질이 스테로이드인 조성물.
  6. 제1항에 있어서, 최소한 하나 이상의 약물학적 활성물질이 프로게스토겐, 에스트로겐 또는 이들의 혼합물로 구성되는 조성물.
  7. 제6항에 있어서, 프로게스토겐은 노르에틴드론 또는 노르에틴드론 아세테이트이고, 에스트로겐은 에스트라디올인 조성물.
  8. 다음으로 구성되는 최소한 하나 이상의 약물학적 활성물질의 경피투여용 시스템. (a) 최소한 하나 이상의 약물학적 활성물질의 공급처; (b) 디에틸렌글리콜모노에틸에테르, 디에틸렌글리콜모노메틸에테르, 및 그들의 혼합물로 구성되는 군에서 선택된 에테르성분과, 구조식[CH3(CH2)m COO]nR (여기서 m은 8 내지 16범위의 정수, n은 1 또는 2 및 R은 하나 또는 두개의 히드록실기로 치환 또는 무치환 저급알킬(C1-C3) 잔기이다.)로 주어지는 에스테르 성분으로 이루어지는 투과증진제조성물의공급처; 및 (c0 활성물질과 증진제의 조성물이 피부에 전달되는 상태로 시스템을 유지시키는 장치.
  9. 제8항에 있어서, n이 10인 조성물.
  10. 제8항에 있어서, 에테르성분은 디에틸렌글리콜모노에틸에테르이고 에스테르 성분은 프로필렌 글리콜 모노로레이트 이거나 또는 프로필렌 글리콜 디로레이트와 프로필렌 글리콜 모노노레이트를 같은 쓰는 시스템.
  11. 제9항에 있어서, 최소한 하나 이상의 약물학적 활성물질이 스테로이드인 시스템.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910701172A 1989-03-22 1990-03-19 피부투과증진제조성물 KR950010324B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US327,312 1989-03-22
US327312 1989-03-22
US07/327,312 US4973468A (en) 1989-03-22 1989-03-22 Skin permeation enhancer compositions
PCT/US1990/001469 WO1990011064A1 (en) 1989-03-22 1990-03-19 Skin permeation enhancer compositions

Publications (2)

Publication Number Publication Date
KR920700601A true KR920700601A (ko) 1992-08-10
KR950010324B1 KR950010324B1 (ko) 1995-09-14

Family

ID=23276050

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701172A KR950010324B1 (ko) 1989-03-22 1990-03-19 피부투과증진제조성물

Country Status (12)

Country Link
US (1) US4973468A (ko)
EP (1) EP0464150B1 (ko)
JP (1) JP2550441B2 (ko)
KR (1) KR950010324B1 (ko)
AT (1) ATE156995T1 (ko)
AU (1) AU629331B2 (ko)
CA (1) CA2012875C (ko)
DE (1) DE69031309T2 (ko)
DK (1) DK0464150T3 (ko)
ES (1) ES2106029T3 (ko)
FI (1) FI914391A0 (ko)
WO (1) WO1990011064A1 (ko)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5229129A (en) * 1989-07-12 1993-07-20 Cygnus Therapeutic Systems Transdermal administration of lisuride
NZ237241A (en) * 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
EP0523150A4 (en) * 1990-04-06 1993-09-29 Pharmetrix Corporation Device and method for enhanced administration of physostigmine
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5453279A (en) * 1992-04-21 1995-09-26 Tbs Laboratories, Inc. Enhancing transdermal absorption compositions; transdermal dosage form; and process
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
JPH0827003A (ja) * 1994-07-22 1996-01-30 Sekisui Chem Co Ltd 経皮吸収製剤
AU702593B2 (en) 1994-09-14 1999-02-25 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery
GB9500116D0 (en) * 1995-01-05 1995-03-01 Ciba Geigy Ag Pharmaceutical compositions
US5573778A (en) * 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
EP1563788B8 (en) 1995-08-29 2015-04-08 Nitto Denko Corporation Microporation of human skin for drug delivery and monitoring applications
DE19548332A1 (de) * 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
AU2036297A (en) * 1996-03-20 1997-10-10 Glaxo Group Limited Topical formulations of aciclovir
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
AU4990797A (en) * 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
CN1231593A (zh) * 1996-10-30 1999-10-13 瑟垃技术有限公司 作为渗透促进剂的乳酸盐的脂肪酸酯
KR100215027B1 (ko) * 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
KR100294084B1 (ko) * 1998-06-02 2001-09-22 성재갑 비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
AU1728099A (en) 1997-12-22 1999-07-12 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
AU749475B2 (en) * 1998-04-27 2002-06-27 Astellas Pharma Inc. Medicinal compositions
FR2761600B1 (fr) 1998-06-19 2000-03-31 Oreal Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
GB9825402D0 (en) † 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
US20030078499A1 (en) * 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
AU2002316053A1 (en) 2001-05-01 2002-11-11 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
ES2331302T3 (es) 2001-05-01 2009-12-29 A.V. Topchiev Institute Of Petrochemical Synthesis Composiciones de hidrogel.
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
DK1450804T3 (da) * 2001-11-29 2009-01-05 3M Innovative Properties Co Farmaceutiske formulelringer, der omfatter et immunsvarmodificerende middel
DE10159120B4 (de) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
CA2929300C (en) 2002-03-11 2019-04-16 Nitto Denko Corporation Transdermal drug delivery patch system, method of making same and method of using same
US8116860B2 (en) 2002-03-11 2012-02-14 Altea Therapeutics Corporation Transdermal porator and patch system and method for using same
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
US20030199584A1 (en) * 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
ES2323127T3 (es) * 2002-08-20 2009-07-07 Euro-Celtique S.A. Forma posologica transdermica que comprende un agente activo y una forma de sal y una forma de base libre de un antagonista.
AU2003286736A1 (en) 2002-10-28 2004-05-25 Transform Pharmaceuticals, Inc. Transdermal assay with magnetic clamp
ATE295726T1 (de) * 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
CA2453013C (en) * 2002-12-13 2011-02-15 Gary W. Cleary Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US20040241223A1 (en) * 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
US7576226B2 (en) * 2003-06-30 2009-08-18 Richter Gedeon Vegyeszeti Gyar Rt. Process of making isomers of norelgestromin and methods using the same
US7888546B2 (en) 2003-07-03 2011-02-15 Corium International, Inc. Wound dressing, ingredient delivery device and IV hold-down, and method relating to same
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
CA2554649C (en) 2004-01-30 2015-10-27 Corium International, Inc. Rapidly dissolving film for delivery of an active agent
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
BRPI0513279A (pt) * 2004-07-15 2008-05-06 Freedom 2 Llc pigmento de marcação de tecido modificado e método para modificar o pigmento de marcação de tecido
KR20070048229A (ko) 2004-08-05 2007-05-08 코리움 인터네셔널, 인크. 접착제 조성물
WO2006091697A1 (en) 2005-02-23 2006-08-31 Psychenomics, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other cns indications
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
DE102006050558B4 (de) * 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
US20100278935A1 (en) * 2007-07-30 2010-11-04 Stacey William C Immune System Modulator Formulation
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
US8609733B2 (en) * 2008-05-19 2013-12-17 Massachusetts Institute Of Technology Sensory-specific local anesthesia and prolonged duration local anesthesia
US8658699B2 (en) * 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
AU2010204986B2 (en) 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
US9119578B2 (en) 2011-04-29 2015-09-01 Seventh Sense Biosystems, Inc. Plasma or serum production and removal of fluids under reduced pressure
WO2010101625A2 (en) 2009-03-02 2010-09-10 Seventh Sense Biosystems, Inc. Oxygen sensor
US9295417B2 (en) 2011-04-29 2016-03-29 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
WO2012018486A2 (en) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
CN104434136A (zh) * 2009-03-02 2015-03-25 第七感生物系统有限公司 用于抽出血液的装置
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
WO2011000210A1 (zh) * 2009-07-01 2011-01-06 润和生物医药科技(汕头)有限公司 促渗剂组合物及其透皮给药系统中的应用
AU2010279384A1 (en) 2009-08-05 2012-03-01 Wake Forest University Compositions and methods for inducing apoptosis in prostate cancer cells
WO2011094573A1 (en) 2010-01-28 2011-08-04 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
WO2011163347A2 (en) 2010-06-23 2011-12-29 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
JP2013538069A (ja) 2010-07-16 2013-10-10 セブンス センス バイオシステムズ，インコーポレーテッド 流体移動デバイスのための低圧環境
US20120039809A1 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
WO2012064802A1 (en) 2010-11-09 2012-05-18 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
EP3087919B2 (en) 2011-04-29 2022-04-13 Seventh Sense Biosystems, Inc. Receiving fluids
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
CA2846121A1 (en) * 2011-08-25 2013-02-28 Nipro Patch Co., Ltd. Hydrous adhesive skin patch
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014018439A8 (pt) * 2012-01-26 2017-07-11 Therapeuticsmd Inc Terapias de reposição de hormônio transdérmica
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014113541A1 (en) 2013-01-16 2014-07-24 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine
JP6313420B2 (ja) 2013-03-15 2018-04-18 ザ チルドレンズ メディカル センター コーポレイション 持続する局所麻酔のためのネオサキシトキシン併用製剤
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
AU2014352920A1 (en) 2013-11-22 2016-06-23 Genzyme Corporation Novel methods for treating neurodegenerative diseases
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
WO2015179782A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3297660A2 (en) 2015-05-20 2018-03-28 The Broad Institute Inc. Shared neoantigens
JP7257739B2 (ja) * 2015-07-02 2023-04-14 ノーヴェン ファーマシューティカルズ インコーポレイテッド レボノルゲストレルおよびエチニルエストラジオールのための経皮的薬物送達システム
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3964482A (en) * 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3923989A (en) * 1973-07-13 1975-12-02 Sandoz Ag Nitro substituted picolinonitriles as anti-bacterial and anti-fungal agents
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4440771A (en) * 1982-02-12 1984-04-03 The United States Of America As Represented By The Secretary Of The Army 2-Acetyl quinoline thiosemicarbazones useful in treatment of gonorrhea, malaria or bacterial infections
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
US4559222A (en) * 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4818540A (en) * 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
US4717568A (en) * 1985-08-09 1988-01-05 Alza Corporation Laminar arrangement for increasing delivery of beneficial agent from dispenser
ZA87332B (en) * 1986-02-27 1987-08-26 Warner Lambert Co Compositions containing fixed combinations
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
CH674618A5 (ko) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US4783450A (en) * 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US4764379A (en) * 1987-08-24 1988-08-16 Alza Corporation Transdermal drug delivery device with dual permeation enhancers

Also Published As

Publication number Publication date
DE69031309T2 (de) 1998-01-08
ATE156995T1 (de) 1997-09-15
JPH04505157A (ja) 1992-09-10
FI914391A0 (fi) 1991-09-18
ES2106029T3 (es) 1997-11-01
JP2550441B2 (ja) 1996-11-06
AU5417490A (en) 1990-10-22
DE69031309D1 (de) 1997-09-25
WO1990011064A1 (en) 1990-10-04
US4973468A (en) 1990-11-27
CA2012875A1 (en) 1990-09-22
DK0464150T3 (da) 1997-09-15
EP0464150B1 (en) 1997-08-20
EP0464150A4 (en) 1993-04-14
KR950010324B1 (ko) 1995-09-14
EP0464150A1 (en) 1992-01-08
AU629331B2 (en) 1992-10-01
CA2012875C (en) 1995-12-05

Similar Documents

Publication Publication Date Title
KR920700601A (ko) 피부투과 증진제 조성물
CA2183543C (en) Sexual steroid-containing transdermal therapeutic systems
KR970706021A (ko) N-치환-o-톨루이딘유도체로 이루어진 약용배합제 및 경피흡수형제제(MEDICINAL ADJUVANTS CONSISTIONG OF AN N-SUBSTITUED-o-TOLUIDING DERIVANTIVE, AND PERCUTANEOUSLY ABSORBALE PREPARATIONS COMPRISING THE ADJUVANTS)
DE69828958T2 (de) Arzneiformulierungen zur hormonersatztherapie zur topischen anwendung auf der haut
ES2261570T3 (es) Medicamento basado en gestagenos para aplicacion por via dermica que contiene acido ascorbico asi como sales del mismo.
KR950031057A (ko) 에스트로겐 및/또는 프로게스토겐을 투여하기 위한 스티렌-이소프렌-스티렌 공중합체로 이루어진 경피성 매트릭스 시스템
KR860000065A (ko) 국부적이고 계통적인 약물의 경피 및 전위막 침투를 증강시키는 조성물 및 방법
EP0091964A1 (en) Base composition for preparing medicine for external application, medicinal composition for external application, and method for accelerating percutaneous absorption of medicinal agent
GB2212723A (en) Skin permeation enhancer compositions using glycerol monooleate
KR19990035795A (ko) 호르몬 패치
KR850004389A (ko) 경피침투가 증진된 생리학적 활성제제의 제조방법
KR890009968A (ko) 신규의 11-아릴스테로이드 화합물
EP0971708B1 (en) Nimesulide gel systems for topical use
ES2133380T3 (es) Composiciones farmaceuticas que contienen glicosidos de antraciclina unidos a derivados polimeros, y su procedimiento de preparacion.
US3888995A (en) Fatty alcohol-propylene glycol vehicle
KR880002524A (ko) 니코란딜 외용제
CA2028604A1 (en) Injectable formulation for lipophilic drugs
KR910015286A (ko) 알킬 사카라이드(saccharides)를 함유하는 제약조성물 및 약물투과를 향상시키기 위한 알킬 사카라이드의 용도
WO1995005137A1 (en) Transdermal delivery system using a combination of permeation enhancers
KR900003174A (ko) 벤조푸로[3,2-c] 퀴놀린 화합물
JP2648960B2 (ja) 外用医薬組成物
SE7507413L (sv) Galenisk beredning.
GB1488995A (en) Compositions containing anti-androgenic compounds
GB1188589A (en) Pharmaceutical Composition for External Application and a method for producing thereof
AU724308B2 (en) Transdermal therapeutic systems that contain sex steroids

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19980901

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee